title: [The clinical efficacy of all-trans retinoic acid plus arsenic trioxide in 177 newly diagnosed acute promyelocytic leukemia patients].
abstract: OBJECTIVE
  To investigate the clinical efficacy of all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) in induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia (APL).
  
  
  METHODS
  A retrospective analysis of 298 newly diagnosed APL patients from the department of hematology, First Affiliated Hospital of Zhejiang University since September 2004 to December 2013, including 177 cases with ATRA plus ATO and 116 ATRA plus chemotherapy (CT), was performed to investigate the clinical efficacy between the low-intermediate (WBC≤10×10⁹/L) and high (WBC>10×10⁹/L) risk APL patients, respectively.
  
  
  RESULTS
  For the low-intermediate risk patients, the relapse rate in ATRA plus CT and ATRA plus ATO are 22.0% and 6.1% (P=0.004), respectively; the 3 years estimated relapse-free survival (RFS) are 78.0% and 92.9% (P=0.021), respectively. For the high risk patients, the relapse rate in ATRA plus CT and ATRA plus ATO are 25.0% and 5.2% (P=0.035), respectively; the 3 years estimated RFS rate were 80.8% and 93.0% (P=0.021), respectively. But the rate of early death (ED), complete remission (CR) and overall survival (OS) between the two therapy protocols had no statistical difference (P>0.05).
  
  
  CONCLUSIONS
  ATRA plus ATO in induction and maintenance therapy might prolong the RFS time of the low-intermediate risk APL patients and decrease the relapse rate of the low, intermediate and high risk APL patients.
authors.affiliation: Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Lu
authors.affiliation: Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
authors.forename: Fenglin
authors.initials: F
authors.lastname: Li
authors.affiliation: Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
authors.forename: Qitian
authors.initials: Q
authors.lastname: Mu
authors.affiliation: Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
authors.forename: Haitao
authors.initials: H
authors.lastname: Meng
authors.affiliation: Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
authors.forename: Wenbin
authors.initials: W
authors.lastname: Qian
authors.affiliation: Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
authors.forename: Hongyan
authors.initials: H
authors.lastname: Tong
authors.affiliation: Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
authors.forename: Wenyuan
authors.initials: W
authors.lastname: Mai
authors.affiliation: Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
authors.forename: Renzhi
authors.initials: R
authors.lastname: Pei
authors.affiliation: Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
authors.forename: Mengxia
authors.initials: M
authors.lastname: Yu
authors.affiliation: Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Jin
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D000077237:Arsenic Trioxide; D001152:Arsenicals; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute; D010087:Oxides; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D014212:Tretinoin
chemical_list: D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide